Last reviewed · How we verify
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) \[Part A: Dose Escalation\] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs \[Part B: Dose Expansion\].
Details
| Lead sponsor | Janssen Research & Development, LLC |
|---|---|
| Phase | PHASE1 |
| Status | ACTIVE_NOT_RECRUITING |
| Enrolment | 70 |
| Start date | Wed Dec 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Aug 31 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Lymphoma, Non-Hodgkin
Interventions
- JNJ-87801493
- JNJ-80948543
- JNJ-75348780
Countries
Denmark, Israel, Australia, Spain